Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
A Phase 1/2, Open Label, Multicenter Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory CD20+ B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Sponsor: Mustang Bio
Terminated
Business reasons
Other terminated trials from Mustang Bio
- B-cell Lymphoma Refractory · Apr 2024
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · Phase PHASE1/PHASE2 · May 2023
More terminations from Mustang Bio
Other B-cell Lymphoma Refractory trials with similar outcome
This PHASE1/PHASE2 trial investigates B-cell Lymphoma Refractory and Chronic Lymphoid Leukemia in Relapse and is currently terminated or withdrawn. Mustang Bio leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Status: Recruiting → Terminated
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Mar 2023 — Sep 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mustang Bio
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .